TY - JOUR
AU - A. H. Lékó
AU - L. Leggio
A1 - 
AB - The cornerstone in managing alcohol-associated liver disease is the treatment of alcohol use disorder (AUD). Several barriers prevent the implementation of adequate treatment and integrated care models. There are patient-level barriers, including the lack of self-awareness of AUD and being ashamed of AUD. There are clinician-level barriers, including lack of training and discomfort in managing patients with AUD. There are system-level barriers, including challenges related to insurance-based health care systems, and the general reluctance to invest in AUD by organizations focused on for-profit milestones. Therefore, it is imperative to develop multidisciplinary hepatology/addiction integrated care approaches.
AD - Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, 251 Bayview Boulevard, Baltimore, MD 21224, USA; Department of Psychiatry and Psychotherapy, Semmelweis University, Balassa utca 6, 1083, Budapest, Hungary.; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, 251 Bayview Boulevard, Baltimore, MD 21224, USA; Department of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, School of Public Health, Brown University, 121 South Main Street, Providence, RI 02903, USA; Division of Addiction Medicine, Department of Medicine, School of Medicine, Johns Hopkins University, 4940 Eastern Avenue, Baltimore, MD 21224, USA; Department of Neuroscience, Georgetown University Medical Center, 3970 Reservoir Road Northwest, NRB, EP04, Washington, DC, USA. Electronic address: lorenzo.leggio@nih.gov.
AN - 39362721
BT - Clin Liver Dis
C5 - Opioids & Substance Use
CP - 4
DA - Nov
DO - 10.1016/j.cld.2024.06.012
DP - NLM
ET - 20240801
IS - 4
JF - Clin Liver Dis
LA - eng
N2 - The cornerstone in managing alcohol-associated liver disease is the treatment of alcohol use disorder (AUD). Several barriers prevent the implementation of adequate treatment and integrated care models. There are patient-level barriers, including the lack of self-awareness of AUD and being ashamed of AUD. There are clinician-level barriers, including lack of training and discomfort in managing patients with AUD. There are system-level barriers, including challenges related to insurance-based health care systems, and the general reluctance to invest in AUD by organizations focused on for-profit milestones. Therefore, it is imperative to develop multidisciplinary hepatology/addiction integrated care approaches.
PY - 2024
SN - 1089-3261 (Print); 1089-3261
SP - 779
EP - 791+
ST - Barriers to Alcohol Use Disorder Treatment in Patients with Alcohol-Associated Liver Disease
T1 - Barriers to Alcohol Use Disorder Treatment in Patients with Alcohol-Associated Liver Disease
T2 - Clin Liver Dis
TI - Barriers to Alcohol Use Disorder Treatment in Patients with Alcohol-Associated Liver Disease
U1 - Opioids & Substance Use
U3 - 10.1016/j.cld.2024.06.012
VL - 28
VO - 1089-3261 (Print); 1089-3261
Y1 - 2024
ER -